Please login to the form below

Not currently logged in
Email:
Password:

Cancer drug, Oxaliplatin, approved for UK

Colon and rectum cancer drug, Oxaliplatin, has been approved for use in the UK

Onco Therapies Ltd (OTL), a subsidiary of Strides Arcolab, has announced that its colon and rectum cancer drug, Oxaliplatin, has been approved through a decentralised procedure for use in the UK. Approval across other European countries is expected shortly.

The drug will be manufactured at Strides' oncology complex in Bangalore, India, and used to treat advanced cancer of the colon and rectum in combination with other medicines to slow or stop cancer cell growth. It will be administered as a 5mg/ml injection.

Oxaliplatin is one of 37 drugs licensed to Pfizer on a semi-exclusive basis for sales in 17 European countries.

This is the second European approval out of 22 filings made by the OTL in 2010, for products with a combined market value of over $5bn.

15th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics